Maximizing ROI in Pharma: A Deep Dive into AI Use Case Prioritization
The prioritization grid for generative AI use cases in the pharmaceutical industry provides a comprehensive overview of various use cases FFI-Ventures is working on today and within the last 18 months. The grid outlines the potential business impact, and technical feasibility of use cases but also indicates use cases that offer the highest return on investment (ROI).
It is key to mention that Business Impact and ROI are not the same: Business impact addresses the need to solve a critical problem, whereas the related ROI to a use cases shows the Return on Investment on the money invested within a year time.
Key highlights from the prioritization grid
Quick Wins: The upper right quadrant showcases high-impact, easily implementable use cases like regulatory intelligence, tutoring companions, and message development. These offer substantial ROI with relatively low technical barriers.
Scale-up Opportunities: The upper left quadrant features high-impact but more technically challenging projects such as drug molecule generators, HTA dossier builders, and CSR writers. These may require significant investment but promise substantial long-term returns.
Good to Have: The lower right quadrant includes useful but lower-impact tools like knowledge agents and congress reporters. While beneficial, these may not be top priorities for immediate investment.
Deprioritize: The lower left quadrant contains projects with both low business impact and technical feasibility, suggesting they should be given lower priority in resource allocation.
Our grid also uses bubble sizes to indicate ROI potential, with larger bubbles representing higher expected returns. This visual cue helps decision-makers quickly identify the most promising opportunities across different pharmaceutical functions, including medical, commercial, R&D, and quality & manufacturing.
See the recording on this topic from our Webinar held on July 3, 2024
FFI-Ventures offers a wide range of tools to identify, prioritize and pull-through generative use cases, including a proved ROI-framework.
We’re supporting pharmaceutical companies making informed decisions about where to invest their AI resources, ensuring they focus on use cases that offer the best balance of business impact, technical feasibility, and potential ROI.
Why FFI-Ventures?
- With extensive experience in Pharma & Medical Affairs, FFI deeply understands the unique challenges and requirements of Medical Affairs teams.
- FFI combines its generative AI expertise with an in-house agency, ensuring solutions are tailored to your specific needs and grounded in real-world practicality.
- Proven Track Record as FFI has successfully implemented private generative AI solutions for numerous healthcare companies, demonstrating its ability to drive tangible results and return on investment.
Generative AI is here to stay! By partnering with FFI, you’ll gain a trusted ally with the expertise to unlock the full potential of this transformative technology, empowering your organization to deliver exceptional value to healthcare professionals and patients alike. Reach out to us!
About OneRay.ai
OneRay.ai is a second-generation, bespoke generative AI solution co-created with medical affairs teams, incorporating a comprehensive set of features tailored to the unique needs within Pharma. Developed through close collaboration and iterative feedback loops, this platform offers a wide array of functionalities highly relevant to medical affairs professionals, such as automated literature summarization, medical content generation, validated data integration from internal and external sources, and specialized features such a medical key messages and behaviour change integration for engaging healthcare professionals and patients compliantly.